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Which One Are We Talking About?*Blase A. Carabello, MDA s emphasized in the 2014 American Collegeof Cardiology/American Heart Associationguidelines for the treatment of valvular heart
disease (1), primary (degenerative) and secondary
(functional) mitral regurgitation (MR) are 2 nearly
separate diseases with different deﬁnitions, different
therapies, and different outcomes. For primary MR,
the disease is MR. Restoration of mitral competence
with mitral repair removes the hemodynamic burden
responsible for the eventual deterioration in left
ventricular (LV) function, may restore LV function
if it was already depressed, and improves both the
quality of life and longevity (2–7).
In secondary MR, the MR is the consequence of
other diseases that have injured the LV. Not surpris-
ingly, curing MR does not cure the myocardial in-
farctions or dilated cardiomyopathy that caused the
MR in the ﬁrst place. Thus, restoration of mitral
competence in this disease does not convincingly
improve longevity, although it does improve quality
of life (8–10). In a recent trial randomizing patients
with secondary MR to receive mitral repair versus
mitral valve replacement, the 1-year mortality was
15%, and mitral repair, the gold standard of therapy
for primary MR, was no better than mitral valve
replacement (10), reﬂecting the differences in therapy
for the 2 diseases.SEE PAGES 172 AND 182With that background, 2 papers in this issue of the
Journal report the results of percutaneous repair us-
ing the MitraClip, a device that reduces MR by* Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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disclose.apposing the two mitral leaﬂets at their midsections
(11,12).
THERAPY FOR PRIMARY MR
As noted above, mitral valve repair is the preferred
therapy for treating primary MR. Repair maintains
LV function and can restore lifespan to normal when
practiced in expert hands and when timed before
severe LV dysfunction has been allowed to occur
(5,13–15). That said, we must look at our collective
selves as a cardiovascular community in the mirror.
A substantial number of cardiologists do not know
the importance of repair, the triggers for referral to a
surgeon, or the repair rate in their own hospitals
(16). Additionally, unfortunately, although some
centers accomplish very high repair rates (17), a
recent query of the Society of Thoracic Surgeons
(STS) database found that the average U.S. surgeon
repaired less than 50% of mitral valves on which
they operated, and on average, U.S. surgeons per-
formed fewer than one-half a dozen mitral opera-
tions of any kind in a year (18). Contrasting this
ﬁnding with coronary revascularization, how many
cardiologists would refer his/her patient to a sur-
geon that used the internal mammary artery to
bypass the left anterior descending artery <50% of
the time and performed only 6 coronary surgeries
per year? Enter the MitraClip as a potential alter-
native to the low surgical repair rates noted above.
Lim et al. (11) report the early and 1-year outcomes
of 127 patients with primary MR treated with the
MitraClip, who were judged to be at prohibitive risk
for surgery. By far, the most impressive ﬁnding in
this elderly group of very ill patients was their
improvement in their quality of life. Of the 75% who
survived to 1 year, SF-36 scores and NYHA func-
tional class improved dramatically. As there was
neither a medical nor surgical control group, we
cannot know how “clip” therapy might have
compared to those therapies. Although there is no
Carabello J A C C V O L . 6 4 , N O . 2 , 2 0 1 4
Therapy for Mitral Regurgitation J U L Y 1 5 , 2 0 1 4 : 1 9 3 – 5
194medical therapy for primary MR per se, there are
indeed standard therapies for heart failure. These
therapies are generally recommended even when
heart failure is caused by primary MR, but their
success in this disease is unknown because patients
with severe valvular heart disease have been ex-
cluded from heart failure trials. Although the use of
these therapies is not discussed, they should at least
be considered when heart failure intervenes in pri-
mary MR. How patient outcomes in this study would
have compared with those of standard surgical
mitral repair is obviously unknown.
The authors’ determination of prohibitive risk
seems fair, but pulmonary hypertension and risk of
aspiration seem somewhat arbitrary as many pa-
tients with either condition can undergo an opera-
tion safely, albeit at higher than average risk.
Furthermore, the fact that a few patients underwent
surgery vitiates the term prohibitive because Web-
ster deﬁnes “prohibitive” as “serving as to preclude
the use of something.” Obviously, surgery was not
precluded. It has become obvious that no risk score
fully can account for all the variables that enter
into the risk of surgery, although the STS score
seems to give a good, although often overestimated,
appraisal of risk (19). Regardless, no score should
supersede the judgment of a heart team that takes
into account both the tangible and intangible factors
that contribute to surgical risk, and in the patients
reported here, surgery was considered infeasible.
That said, we in the medical community must do
a better job of standardizing our terminology.
Different device trials now use the terms inoperable,
extreme risk, high risk, prohibitive risk, and inter-
mediate risk to classify risk, yet patients of similar
risk in 1 trial might be categorized quite differently
in another.
Mitral regurgitation was reduced but not elimi-
nated by MitraClip therapy, but it does not neces-
sarily have to be. Animal data demonstrate, and
human data suggest, that reduction in MR severity to
a regurgitant fraction of approximately one-third
(moderate MR) allows for reverse remodeling and
improved muscle function, if it was previously
depressed (20,21). The problem with leaving the pa-
tient with this much MR is that it predicts eventual
recurrence of severe MR. However, this is not of
particular concern in the aged patients in this study,
where impaired longevity of the patient reduced the
need for repair durability. Nonetheless, we must take
a cautionary note from Lim et al. (11) when severe MR
remains after the procedure. When patients were
discharged with grade 3þ or 4þ MR, their 1-year
mortality exceeded 50%, an extraordinarily highﬁgure. While there is no way to know if there was a
cause-and-effect relationship, operators must at least
consider this statistic.
THERAPY FOR SECONDARY MR
The ultimate therapy for secondary MR should be to
restore the contractile elements or the force genera-
tion of those elements, thereby returning ventricular
function to normal, allowing the LV to remodel in
such a way as to restore mitral competence. Although
such therapies hold promise for the future, they
currently are unavailable for general use. Accord-
ingly, we treat patients with secondary MR by using
guideline-driven therapies for the heart failure that
the patients almost inevitably have. This distinction
for secondary MR patients derives from the fact that
MR is not the primary cause of heart failure but
rather a complication of it. Not surprisingly, surgery
has produced disappointing results with regard to
increasing lifespan, because it does not cure the loss
of contractility that caused the MR in the ﬁrst place
(8–10). However, surgery does improve symptoms in
some but not all cases. Thus, the bar for treating this
disease is much lower than it is for primary MR.
Accordingly, it is harder to draw conclusions from the
paper by Glower et al. (12), where patients with the
2 different diseases were admixed (70% had func-
tional MR) (13). High risk was deﬁned by both the STS
score and/or the presence of pre-speciﬁed risk fac-
tors. Thirty-day mortality (4.8%) and 1-year mortality
(23%) were remarkably similar to the pure primary
MR group reported by Lim et al. (11). Eighty-six
percent had post-procedure MR severity of moder-
ate or less. As in the study by Lim et al. (11), there was
signiﬁcant improvement in quality of life following
the “clip” procedure. Although in this study, it was
impossible to tease out differences in primary and
secondary MR, which surely existed, future reports
will surely be aimed at this discrimination.
WHAT HAVE WE LEARNED FROM
THESE STUDIES?
The 2 studies noted above demonstrate that reduc-
tion in MR improves the quality of life in patients at
increased risk for surgical repair. They clearly de-
monstrate the efﬁcacy of a new tool to treat such
patients. They also suggest a “threshold” phenome-
non for the reduction of MR to have beneﬁcial effects.
Thus, we can treat inoperable patients without
entirely correcting MR in the short run. Although
allowing the persistence of mild to moderate MR is
not wise in patients expected to have extended
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195longevity because of the likelihood of recurrent
severe MR, in elderly patients and those with multi-
ple comorbidities, the presence of post-proceduremild
to moderate MR does not prevent a positive outcome.
For secondary MR, where there is no proof that
surgery prolongs life, this less invasive therapy would
appear ideal. Two trials underway (COAPT [Cardio-
vascular Outcomes Assessment of the MitraClip
Therapy Percutaneous Therapy for High Surgical Risk
Patients] and RESHAPE [A Randomized Study of the
MitraClip Device in Heart Failure Patients With
Clinically Signiﬁcant FunctionalMitral Regurgitation])
should help clarify the therapeutic position of the
MitraClip in patients with secondary MR.In the future, to fully understand the role of
percutaneous MR repair, we must study it separately
in the 2 very different diseases for which it is
being applied, so we can deﬁne its role in primary
versus secondary MR. Furthermore, we must more
precisely deﬁne our terms used to stratify risk in
randomized trials to fully apply the trial results to our
patients.
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